{"doi":"10.1128/aac.01275-23","title":"Sub-MIC levels of bedaquiline and clofazimine can select\n            <i>Mycobacterium tuberculosis</i>\n            mutants with increased MIC","abstract":"<jats:title>ABSTRACT</jats:title>\n          <jats:sec>\n            <jats:title/>\n            <jats:p>\n              Multidrug-resistant tuberculosis (MDR-TB) patients not cured at the time of stopping treatment are exposed to Minimum Inhibitory Concentration (MIC) and sub-MIC levels for many months after discontinuing bedaquiline (BDQ) or clofazimine (CFZ) treatment.\n              <jats:italic>In vitro</jats:italic>\n              cultures treated with BDQ and CFZ sub-MIC concentrations clearly showed enrichment in the\n              <jats:italic>Rv0678</jats:italic>\n              mutant population, demonstrating that pre-existing\n              <jats:italic>Rv0678</jats:italic>\n              mutants can be selected by sub-MIC concentrations of BDQ and CFZ if not protected by an alternative MDR-TB treatment.\n            </jats:p>\n          </jats:sec>","journal":"Antimicrobial Agents and Chemotherapy","year":2024,"id":608290,"datarank":0.29188652235829704,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.0,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1562186,"name":"Frederik Stevenaert","orcid":"0009-0009-6020-0753","position":1,"is_corresponding":false},{"id":1409260,"name":"Bart Remmerie","orcid":"0000-0003-1775-4194","position":2,"is_corresponding":false},{"id":1548837,"name":"Koen Andries","orcid":null,"position":3,"is_corresponding":false},{"id":1562185,"name":"Cristina Villellas","orcid":"0009-0005-9196-5899","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Sub-MIC levels of bedaquiline and clofazimine can select\n            <i>Mycobacterium tuberculosis</i>\n            mutants with increased MIC","abstract":"<jats:title>ABSTRACT</jats:title>\n          <jats:sec>\n            <jats:title/>\n            <jats:p>\n              Multidrug-resistant tuberculosis (MDR-TB) patients not cured at the time of stopping treatment are exposed to Minimum Inhibitory Concentration (MIC) and sub-MIC levels for many months after discontinuing bedaquiline (BDQ) or clofazimine (CFZ) treatment.\n              <jats:italic>In vitro</jats:italic>\n              cultures treated with BDQ and CFZ sub-MIC concentrations clearly showed enrichment in the\n              <jats:italic>Rv0678</jats:italic>\n              mutant population, demonstrating that pre-existing\n              <jats:italic>Rv0678</jats:italic>\n              mutants can be selected by sub-MIC concentrations of BDQ and CFZ if not protected by an alternative MDR-TB treatment.\n            </jats:p>\n          </jats:sec>","is_dataset_classified":null,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38470194","pmcid":"PMC10989023","openalex_id":"https://openalex.org/W4392892739","authors":[],"funders":[],"total_grants":0,"fwci":1.9321,"citation_percentile":0.84841319,"influential_citations":0,"citation_trend":[{"year":2025,"count":3},{"year":2026,"count":3}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.1128/aac.01275-23","host_type":"journal"},{"url":"https://doi.org/10.1128/aac.01275-23","host_type":"publisher"},{"url":"https://journals.asm.org/doi/pdf/10.1128/aac.01275-23","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38470194","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10989023","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10989023/pdf/aac.01275-23.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC10989023","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10989023?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Tuberculosis Research and Epidemiology","Mycobacterium research and diagnosis","Cancer therapeutics and mechanisms","Humans","Mycobacterium tuberculosis","Clofazimine","Antitubercular Agents","Diarylquinolines","Tuberculosis, Multidrug-Resistant","Microbial Sensitivity Tests"],"mesh_terms":["Antitubercular Agents","Clofazimine","Humans","Microbial Sensitivity Tests","Mycobacterium tuberculosis","Tuberculosis, Multidrug-Resistant","Diarylquinolines"],"keywords":["Bedaquiline","Clofazimine","Tuberculosis","Microbiology","Minimum inhibitory concentration","Mycobacterium tuberculosis","Tb treatment","Multiple drug resistance","Biology","Medicine","Drug resistance","Antibiotics","Immunology","Pathology","Rv0678"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T08:09:31.127326Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}